• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Advances in Targeted Therapy for Breast Cancer.乳腺癌靶向治疗的进展
Fed Pract. 2015 May;32(Suppl 4):46S-49S.
2
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.绝经后激素受体阳性、HER2 阴性转移性乳腺癌患者的内分泌治疗与化疗：系统评价和网络荟萃分析。
Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.
3
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.在绝经后 HR(+)、HER2(-)晚期乳腺癌中，双重阻断可改善无进展生存期，迎来新纪元。
Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30.
4
Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.无进展生存期终点指标在激素受体阳性晚期乳腺癌治疗中的临床意义
Oncologist. 2016 Aug;21(8):922-30. doi: 10.1634/theoncologist.2015-0366. Epub 2016 Jun 2.
5
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.芳香化酶抑制剂用于治疗绝经后妇女的晚期乳腺癌。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003370. doi: 10.1002/14651858.CD003370.pub2.
6
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.CDK4/6 抑制剂治疗激素受体阳性、HER2 阴性、晚期或转移性乳腺癌患者：美国食品和药物管理局的汇总分析。
Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16.
7
Fulvestrant for hormone-sensitive metastatic breast cancer.氟维司群用于激素敏感性转移性乳腺癌。
Cochrane Database Syst Rev. 2017 Jan 3;1(1):CD011093. doi: 10.1002/14651858.CD011093.pub2.
8
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.一线基于内分泌的治疗在 HR+/HER2-转移性乳腺癌绝经后妇女中的无进展生存：一项网状荟萃分析。
Clin Ther. 2018 Apr;40(4):628-639.e3. doi: 10.1016/j.clinthera.2018.03.004. Epub 2018 Mar 31.
9
Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.激素受体阳性、HER2阴性晚期乳腺癌内分泌治疗的总生存期和无进展生存期：综述
Ther Adv Med Oncol. 2017 Nov;9(11):693-709. doi: 10.1177/1758834017728928. Epub 2017 Sep 8.
10
Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.雷帕霉素哺乳动物靶点抑制剂作为激素受体阳性晚期乳腺癌一线治疗的潜在作用。
Onco Targets Ther. 2015 Dec 7;8:3629-38. doi: 10.2147/OTT.S88037. eCollection 2015.

引用本文的文献

1
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.一项基于生殖系BRCA突变状态的转移性乳腺癌患者中CDK4/6抑制剂治疗模式及结局的真实世界证据研究
Oncol Ther. 2021 Dec;9(2):575-589. doi: 10.1007/s40487-021-00162-4. Epub 2021 Jul 25.
2
Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.拉帕替尼联合局部放射治疗HER-2阳性乳腺癌患者脑转移及曲妥珠单抗的作用：一项系统评价和荟萃分析
Front Oncol. 2020 Nov 6;10:576926. doi: 10.3389/fonc.2020.576926. eCollection 2020.

本文引用的文献

1
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌的治疗
N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
2
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.哌柏西利联合来曲唑与来曲唑单药一线治疗雌激素受体阳性、HER2 阴性、晚期乳腺癌（PALOMA-1/TRIO-18）的随机 2 期研究。
Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.
3
Adjuvant ovarian suppression in premenopausal breast cancer.绝经前乳腺癌的辅助性卵巢抑制
N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.
4
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.绝经前乳腺癌的辅助依西美坦加卵巢抑制。
N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.
5
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.随机对照 CONFIRM 试验：氟维司群 500mg 与 250mg 的最终总生存比较。
J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.
6
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.氟维司群 500 mg 对比阿那曲唑 1 mg 作为晚期乳腺癌一线治疗：来自随机 'FIRST' 研究的随访分析。
Breast Cancer Res Treat. 2012 Nov;136(2):503-11. doi: 10.1007/s10549-012-2192-4. Epub 2012 Oct 13.
7
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
8
Trastuzumab--mechanism of action and use in clinical practice.曲妥珠单抗——作用机制及临床应用
N Engl J Med. 2007 Jul 5;357(1):39-51. doi: 10.1056/NEJMra043186.
9
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.氟维司群（曾用名ICI 182,780）在先前内分泌治疗后病情进展的绝经后晚期乳腺癌女性患者中，其疗效与阿那曲唑相当。
J Clin Oncol. 2002 Aug 15;20(16):3396-403. doi: 10.1200/JCO.2002.10.057.
10
Adjuvant therapy for very young women with breast cancer: need for tailored treatments.非常年轻的乳腺癌女性患者的辅助治疗：需要量身定制的治疗方法。
J Natl Cancer Inst Monogr. 2001(30):44-51. doi: 10.1093/oxfordjournals.jncimonographs.a003459.

乳腺癌靶向治疗的进展

Advances in Targeted Therapy for Breast Cancer.

作者信息

Mener Andrew S, Aggarwal Anita

机构信息

is a fellow in hematology/oncology and is an associate professor of medicine, both at The George Washington University in Washington, DC. Dr. Aggarwal is also an associate professor of medicine at Georgetown University and a hematologist/oncologist at the Washington DC VAMC, both in Washington, DC. She is also president elect of Association of VA Hematology and Oncology..

出版信息

Fed Pract. 2015 May;32(Suppl 4):46S-49S.

PMID:30766121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6375455/
Abstract

Recent clinical trials have provided additional first-line therapeutic treatment options that improve overall survival and progression-free survival in women with breast cancer.

摘要

近期的临床试验提供了更多一线治疗选择，可改善乳腺癌女性患者的总生存期和无进展生存期。